RESUMEN
The design, synthesis, and structure-activity relationship (SAR) for a series of ß-substituted 3-(4-aryloxyaryl)propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model.
Asunto(s)
Hipoglucemiantes/farmacología , Islotes Pancreáticos/efectos de los fármacos , Propionatos/síntesis química , Propionatos/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Ciclización , Modelos Animales de Enfermedad , Hipoglucemiantes/síntesis química , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Concentración 50 Inhibidora , Ratones , Estructura Molecular , Propionatos/química , Propionatos/farmacocinéticaRESUMEN
Systematic structure-activity relationship (SAR) studies of a screening lead led to the discovery of a series of thiazolidinediones (TZDs) as potent GPR40 agonists. Among them, compound C demonstrated an acute mechanism-based glucose-lowering in an intraperitoneal glucose tolerance test (IPGTT) in lean mice, while no effects were observed in GPR40 knock-out mice.
Asunto(s)
Descubrimiento de Drogas/métodos , Receptores Acoplados a Proteínas G/agonistas , Tiazolidinedionas/química , Animales , Ratones , Ratones Noqueados , Unión Proteica/fisiología , Receptores Acoplados a Proteínas G/metabolismo , Relación Estructura-Actividad , Tiazolidinedionas/agonistas , Tiazolidinedionas/farmacologíaRESUMEN
We report SAR studies on a novel non-peptidic bombesin receptor subtype-3 (BRS-3) agonist lead series derived from high-throughput screening hit RY-337. This effort led to the discovery of compound 22e with significantly improved potency at both rodent and human BRS-3.
Asunto(s)
Descubrimiento de Drogas , Imidazoles/química , Imidazoles/farmacología , Receptores de Bombesina/agonistas , Animales , Disponibilidad Biológica , Humanos , Imidazoles/farmacocinética , Ratas , Relación Estructura-ActividadRESUMEN
The atypical chemokine receptor CXCR7 has been studied in various disease settings including immunological diseases and heart disease. Efforts to elucidate the role of CXCR7 have been limited by the lack of suitable chemical tools with a range of pharmacological profiles. A high-throughput screen was conducted to discover novel chemical matter with the potential to modulate CXCR7 receptor activity. This led to the identification of a series of diphenylacetamides confirmed in a CXCL12 competition assay indicating receptor binding. Further evaluation of this series revealed a lack of activity in the functional assay measuring ß-arrestin recruitment. The most potent representative, compound 10 (K i = 597 nM), was determined to be an antagonist in the ß-arrestin assay (IC50 = 622 nM). To our knowledge, this is the first reported small molecule ß-arrestin antagonist for CXCR7, useful as an in vitro chemical tool to elucidate the effects of CXCL12 displacement with ß-arrestin antagonism in models for diseases such as cardiac injury and suitable as starting point for hit optimization directed toward an in vivo tool compound for studying CXCR7 receptor pharmacology.
RESUMEN
Central administration of the neuropeptide melanin-concentrating hormone (MCH) stimulates feeding in rodents. We studied the effects of intracerebroventricular (i.c.v.) administration of an MCH-1 receptor agonist (Compound A) and an MCH-1 receptor antagonist (Compound B) on feeding in satiated rats. Compound B (10 microg, i.c.v.) blocked the acute orexigenic effect of Compound A (5 microg, i.c.v.). In an experiment designed to either stimulate or inhibit MCH-1 receptor signaling over an extended period, rats received continuous i.c.v. infusions of vehicle (saline), Compound A (30 microg/day), Compound B (30 or 48 microg/day) or neuropeptide Y (24 microg/day, as positive control) via implantable infusion pumps. Continuous MCH-1 receptor activation recapitulated the obese phenotype of MCH-over-expressor mice, manifest as enhanced feeding (+23%, P<0.001), caloric efficiency and body weight gain (+38%, P<0.005) over the 14-day period relative to controls. Chronic MCH-1 receptor activation also elevated plasma insulin and leptin levels significantly. Conversely, continuous MCH-1 receptor antagonism led to sustained reductions in food intake (-16%, P<0.001), body weight gain (-35%, P<0.01), and body fat gain relative to controls, without an effect on lean mass. Antagonism of the MCH-1 receptor may be an effective approach for the treatment of obesity.
Asunto(s)
Tejido Adiposo/fisiología , Apetito/fisiología , Peso Corporal/fisiología , Receptores de la Hormona Hipofisaria/fisiología , Tejido Adiposo/efectos de los fármacos , Secuencia de Aminoácidos/fisiología , Animales , Apetito/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ingestión de Alimentos/efectos de los fármacos , Ingestión de Alimentos/fisiología , Éteres/administración & dosificación , Éteres/química , Hidrocarburos Fluorados/administración & dosificación , Hidrocarburos Fluorados/química , Masculino , Datos de Secuencia Molecular , Ratas , Ratas Sprague-Dawley , Receptores de la Hormona Hipofisaria/agonistas , Receptores de la Hormona Hipofisaria/antagonistas & inhibidores , Receptores de la Hormona Hipofisaria/químicaRESUMEN
OBJECTIVE: Acute activation of G protein-coupled receptor 40 (GPR40) by free fatty acids (FFAs) or synthetic GPR40 agonists enhances insulin secretion. However, it is still a matter of debate whether activation of GPR40 would be beneficial for the treatment of type 2 diabetes, since chronic exposure to FFAs impairs islet function. We sought to evaluate the specific role of GPR40 in islets and its potential as a therapeutic target using compounds that specifically activate GPR40. RESEARCH DESIGN AND METHODS: We developed a series of GPR40-selective small-molecule agonists and studied their acute and chronic effects on glucose-dependent insulin secretion (GDIS) in isolated islets, as well as effects on blood glucose levels during intraperitoneal glucose tolerance tests in wild-type and GPR40 knockout mice (GPR40(-/-)). RESULTS: Small-molecule GPR40 agonists significantly enhanced GDIS in isolated islets and improved glucose tolerance in wild-type mice but not in GPR40(-/-) mice. While a 72-h exposure to FFAs in tissue culture significantly impaired GDIS in islets from both wild-type and GPR40(-/-) mice, similar exposure to the GPR40 agonist did not impair GDIS in islets from wild-type mice. Furthermore, the GPR40 agonist enhanced insulin secretion in perfused pancreata from neonatal streptozotocin-induced diabetic rats and improved glucose levels in mice with high-fat diet-induced obesity acutely and chronically. CONCLUSIONS: GPR40 does not mediate the chronic toxic effects of FFAs on islet function. Pharmacological activation of GPR40 may potentiate GDIS in humans and be beneficial for overall glucose control in patients with type 2 diabetes.
Asunto(s)
Glucemia/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/efectos de los fármacos , Receptores Acoplados a Proteínas G/agonistas , Animales , Animales Recién Nacidos , Células CHO , Línea Celular , Cricetinae , Cricetulus , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Grasas de la Dieta/administración & dosificación , Ácidos Grasos/farmacología , Ácidos Grasos no Esterificados/farmacología , Femenino , Humanos , Técnicas In Vitro , Inositol 1,4,5-Trifosfato/metabolismo , Insulina/sangre , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Obesidad/sangre , Obesidad/etiología , Obesidad/metabolismo , Embarazo , Ratas , Ratas Wistar , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/fisiologíaRESUMEN
Structure-activity relationships of a 4-aminoquinoline MCH1R antagonist lead series were explored by synthesis of analogs with modifications at the 2-, 4-, and 6-positions of the original HTS hit. Improvements to the original screening lead included lipophilic groups at the 2-position and biphenyl, cyclohexyl phenyl, and hydrocinnamyl carboxamides at the 6-position. Modifications of the 4-amino group were not well tolerated.
Asunto(s)
Aminoquinolinas/farmacología , Receptores de Somatostatina/antagonistas & inhibidores , Aminoquinolinas/síntesis química , Aminoquinolinas/química , Unión Competitiva , Línea Celular , Evaluación Preclínica de Medicamentos , Humanos , Técnicas In Vitro , Estructura Molecular , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of 2-aminoquinoline compounds was prepared and evaluated in MCH1R binding and functional antagonist assays. Small dialkyl, methylalkyl, methylcycloalkyl, and cyclic amines were tolerated at the quinoline 2-position. The in vivo efficacy of compound 12 was explored and compared to that of a related inactive analog to determine their effects on food intake and body weight in rodents.
Asunto(s)
Quinolinas/farmacología , Quinuclidinas/farmacología , Receptores de Somatostatina/antagonistas & inhibidores , Animales , Unión Competitiva , Bioensayo , Ingestión de Alimentos , Metabolismo Energético/efectos de los fármacos , Humanos , Masculino , Estructura Molecular , Quinolinas/síntesis química , Quinolinas/química , Quinuclidinas/síntesis química , Quinuclidinas/química , Ratas , Ratas Sprague-Dawley , Receptores de Somatostatina/química , Receptores de Somatostatina/genética , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
In mammals, bombesin-like peptides mediate a broad range of physiological functions through binding to three highly conserved G-protein-coupled receptors: the neuromedin B-preferring, the gastrin-releasing peptide-preferring, and the bombesin-receptor subtype 3. Selective modulation of these receptors presents opportunities for the development of novel therapeutics. To ascertain if rhesus monkey could serve as a surrogate animal model for the development of modulators of bombesin-like receptor function, we undertook a search for additional receptor family members and studied the expression profiles of the three known bombesin-related receptors. We found no evidence for additional receptor family members in mammals, suggesting that the expression of the previously described bombesin-receptor subtype 4 is limited to amphibians. We studied the distribution of the three receptors in a broad array of human and rhesus monkey tissues. Based on the similarity between the human and the rhesus expression profiles, we conclude that the rhesus monkey may be a suitable animal model to evaluate the clinical efficacy and potential side effects of bombesin-like peptide ligands.
Asunto(s)
Regulación de la Expresión Génica , Macaca mulatta/genética , Neuroquinina B/análogos & derivados , Receptores de Bombesina/genética , Secuencia de Aminoácidos , Proteínas Anfibias/genética , Proteínas Anfibias/metabolismo , Anfibios/genética , Anfibios/metabolismo , Animales , Péptido Liberador de Gastrina/metabolismo , Regulación de la Expresión Génica/genética , Regulación de la Expresión Génica/fisiología , Humanos , Macaca mulatta/metabolismo , Datos de Secuencia Molecular , Neuroquinina B/metabolismo , Especificidad de Órganos/genética , Receptores de Bombesina/metabolismo , Especificidad de la EspecieRESUMEN
Human melanin-concentrating hormone (hMCH) and many of its analogues are potent but nonspecific ligands for human melanin-concentrating hormone receptors 1 and 2 (hMCH-1R and hMCH-2R). To differentiate between the physiological functions of these receptors, selective antagonists are needed. In this study, analogues of Ac-Arg(6)-cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Gly(10)-Arg(11)-Val(12)-Tyr(13)-Arg(14)-Pro(15)-Cys(16))-NH(2), a high affinity but nonselective agonist at hMCH-1R and hMCH-2R, were prepared and tested in binding and functional assays on cells expressing these receptors. In the new analogues, 5-aminovaleric acid (Ava) was incorporated in place of the Leu(9)-Gly(10) and/or Arg(14)-Pro(15) segments of the disulfide ring. Several of these compounds turned out to be high affinity antagonists selective for hMCH-1R. Moreover, even at micromolar concentrations, they were devoid of agonist potency at both hMCH receptors and not effective as hMCH-2R antagonists. For example, peptide 14, Gva(6)- cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Gly(10)-Arg(11)-Val(12)-Tyr(13)-Ava(14,15)-Cys(16))-NH(2), (Gva = 5-guanidinovaleric acid), was a full competitive hMCH-1R antagonist (IC(50) = 14 nM, K(B) = 0.9 nM) with more than 1000-fold selectivity over hMCH-2R. Examination of various compounds with Ava in positions 9,10 and/or 14,15 revealed that the Leu(9)-Gly(10) and Arg(14)-Pro(15) segments of the disulfide ring are the principal structural elements determining hMCH-1R selectivity and ability to act as a hMCH-1R antagonist.
Asunto(s)
Hormonas Hipotalámicas/antagonistas & inhibidores , Hormonas Hipotalámicas/metabolismo , Melaninas/antagonistas & inhibidores , Melaninas/metabolismo , Péptidos Cíclicos/síntesis química , Péptidos Cíclicos/metabolismo , Hormonas Hipofisarias/antagonistas & inhibidores , Hormonas Hipofisarias/metabolismo , Receptores de la Hormona Hipofisaria/metabolismo , Aequorina/metabolismo , Sustitución de Aminoácidos , Aminoácidos Neutros/química , Aminoácidos Neutros/metabolismo , Animales , Unión Competitiva , Células COS , Línea Celular , Disulfuros/química , Humanos , Hormonas Hipotalámicas/química , Ligandos , Mediciones Luminiscentes , Melaninas/química , Péptidos Cíclicos/farmacología , Hormonas Hipofisarias/química , Conformación Proteica , Ensayo de Unión Radioligante , Receptores Acoplados a Proteínas G , Receptores de la Hormona Hipofisaria/química , TransfecciónRESUMEN
Human melanin-concentrating hormone (hMCH) is a nonselective natural ligand for the human melanin-concentrating hormone receptors: hMCH-1R and hMCH-2R. Similarly, the smaller peptide encompassing the disulfide ring and Arg(6) of hMCH, Ac-Arg(6)-cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Gly(10)-Arg(11)-Val(12)-Tyr(13)-Arg(14)-Pro(15)-Cys(16))-NH(2), Ac-hMCH(6-16)-NH(2), binds to and activates equally well both human MCH receptors present in the brain. To separate the physiological functions of hMCH-1R from those of hMCH-2R, new potent and hMCH-1R selective agonists are necessary. In the present study, analogs of Ac-hMCH(6-16)-NH(2) were prepared and tested in binding and functional assays on cells expressing the MCH receptors. In these peptides, Arg in position 6 was replaced with various d-amino acids and/or Gly in position 10 was substituted with various L-amino acids. Several of the new compounds turned out to be potent agonists at hMCH-1R with improved selectivity over hMCH-2R. For example, peptide 26 with d-Arg in place of L-Arg in position 6 and Asn in place of Gly in position 10, Ac-dArg(6)-cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Asn(10)-Arg(11)-Val(12)-Tyr(13)-Arg(14)-Pro(15)-Cys(16))-NH(2), was a potent hMCH-1R agonist (IC(50) = 0.5 nm, EC(50) = 47 nm) with more than 200-fold selectivity with respect to hMCH-2R. Apparently, these structural changes in positions 6 and 10 results in peptide conformations that allow for efficient interactions with hMCH-1R but are unfavorable for molecular recognition at hMCH-2R.
Asunto(s)
Hormonas Hipotalámicas/agonistas , Hormonas Hipotalámicas/química , Melaninas/agonistas , Melaninas/química , Hormonas Hipofisarias/agonistas , Hormonas Hipofisarias/química , Receptores de la Hormona Hipofisaria/química , Secuencia de Aminoácidos , Animales , Encéfalo/metabolismo , Células CHO , Células COS , Calcio/metabolismo , Cricetinae , Relación Dosis-Respuesta a Droga , Humanos , Técnicas In Vitro , Ligandos , Modelos Químicos , Datos de Secuencia Molecular , Biosíntesis de Péptidos , Péptidos/química , Plásmidos/metabolismo , Conformación Proteica , Receptores Acoplados a Proteínas GRESUMEN
To assess the contribution of potential central nervous system pathways implicated in the control of appetite regulation and energy metabolism, it is essential to first identify appropriate animal models. Melanin-concentrating hormone (MCH), a conserved cyclic neuropeptide implicated in the modulation of food intake, has been shown to bind and activate two G-protein-coupled receptors, called GPR24 and MCHR2, expressed in human brain and other tissues. Here we show that several non-human species (rat, mouse, hamster, guinea pig, and rabbit) do not have functional MCHR2 receptors, or encode a nonfunctional MCHR2 pseudogene while retaining GPR24 expression. We identified three species for further evaluation that express both MCH receptor subtypes. We cloned and functionally characterized dog, ferret, and rhesus GPR24 and MCHR2 in mammalian cells and studied their brain distribution patterns by in situ hybridization. The homology, expression profile, and functional similarity of the receptors in the dog, ferret, and rhesus to that of human support the potential use of these species as preclinical animal models in the development of therapeutic agents for obesity or other MCH-mediated disorders.
Asunto(s)
Mamíferos/genética , Receptores de la Hormona Hipofisaria/genética , Receptores de Somatostatina/genética , Secuencia de Aminoácidos , Animales , Regulación de la Expresión Génica , Humanos , Datos de Secuencia Molecular , Especificidad de Órganos , Receptores Acoplados a Proteínas G , Alineación de Secuencia , Especificidad de la EspecieRESUMEN
By using a combination of genetic, pharmacological, and anatomical approaches, we show that the melanocortin 4 receptor (MC4R), implicated in the control of food intake and energy expenditure, also modulates erectile function and sexual behavior. Evidence supporting this notion is based on several findings: (i) a highly selective non-peptide MC4R agonist augments erectile activity initiated by electrical stimulation of the cavernous nerve in wild-type but not Mc4r-null mice; (ii) copulatory behavior is enhanced by administration of a selective MC4R agonist and is diminished in mice lacking Mc4r; (iii) reverse transcription (RT)-PCR and non-PCR based methods demonstrate MC4R expression in rat and human penis, and rat spinal cord, hypothalamus, brainstem, pelvic ganglion (major autonomic relay center to the penis), but not in rat primary corpus smooth muscle cavernosum cells; and (iv) in situ hybridization of glans tissue from the human and rat penis reveal MC4R expression in nerve fibers and mechanoreceptors in the glans of the penis. Collectively, these data implicate the MC4R in the modulation of penile erectile function and provide evidence that MC4R-mediated proerectile responses may be activated through neuronal circuitry in spinal cord erectile centers and somatosensory afferent nerve terminals of the penis. Our results provide a basis for the existence of MC4R-controlled neuronal pathways that control sexual function.